Wedbush Securities’s Cellectar Biosciences CLRB Stock Holding History

Wedbush Securities’s Portfolio CLRB Stock Details CLRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-149	Closed	-$56K	–	887
2020 Q3	$56K	Buy	149 +15	+11%	+$5.92K	0.01%	871
2020 Q2	$52K	Buy	+134	New	+$56.3K	﹤0.01%	902

Other funds holding CLRB

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Altium Capital Management New York $42M AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Tri Locum Partners New York $713M AUM 68.92% 1-Year Est. Return

Wedbush Securities's CLRB Position: Q4 2020 in Review

Wedbush Securities sold out of Cellectar Biosciences (CLRB) in Q4 2020, closing a stake of 149 shares — an estimated $56K sold.

Wedbush Securities first reported a position in CLRB in Q2 2020 and held it in 2 quarters. The position peaked at $56K in Q3 2020. 39 funds tracked by Wall St. Rank hold CLRB as of Q4 2020.

Wedbush Securities reported no remaining Cellectar Biosciences position as of Q4 2020 after selling out during the quarter.
Wedbush Securities sold 149 Cellectar Biosciences shares in Q4 2020, an estimated $56K.
Wedbush Securities first reported a position in Cellectar Biosciences in Q2 2020 and held it in 2 quarters.
Wedbush Securities's Cellectar Biosciences position peaked at $56K in Q3 2020.
39 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q4 2020.

Based on Wedbush Securities's 13F filing for Q4 2020, filed 16 Feb 2021.